Mankind Pharma Limited
PosiFunda Ratios Only on PositoAI
PositoAI's own ratios from Mankind Pharma Limited's yearly results (2023–2026), compared with Healthcare companies in India. Tap ? on any ratio for what it means.
What stands out
- Tangible Net Worth Ratio: Of every ₹100 of net worth, ₹1 is tangible; the rest is goodwill and other intangibles, often from buying other companies. Less tangible than 97% of Healthcare companies in India.
- Tangible Assets Ratio: Of every ₹100 the company owns, ₹43 is in tangible assets such as plants, cash, stock and receivables; the rest is goodwill and other intangibles. Less tangible than 97% of Healthcare companies in India.
- Self-Funding Ratio: Over the last 3 years its own operating cash covered its investment spending (capex) 4.6 times. Higher than 89% of Healthcare companies in India.
Where ₹100 of sales goes
Latest year (Mar 2026). Taxes and other income are not shown, so the parts need not add up to 100.
Cash quality
Profit Cash Ratio
₹132Over the last 3 years, every ₹100 of reported profit came with ₹132 of operating cash.
Higher than 63% of Healthcare companies in India.
Self-Funding Ratio
4.6×Over the last 3 years its own operating cash covered its investment spending (capex) 4.6 times.
Higher than 89% of Healthcare companies in India.
Cash Locked Ratio
₹14For every ₹100 of sales, ₹14 is tied up in day-to-day operations (money owed by customers + stock − money owed to suppliers), against ₹11 tied up three years earlier.
Less money tied up than 69% of Healthcare companies in India.
Growth quality
Steadiness Ratio
3/3 · 2/3Sales grew in 3 of the last 3 years; profit grew in 2 of 3.
Steadier than 53% of Healthcare companies in India.
Growth Efficiency Ratio
₹11Sales grew 63% in 3 years; of every extra ₹100 of sales, ₹11 became extra profit.
Lower than 64% of Healthcare companies in India.
Asset Productivity Ratio
+63% / +189%In 3 years sales changed by +63% while total assets changed by +189%. Assets grew faster than sales.
Balance-sheet strength
Debt Due Cover Ratio
0.9×Debt due within a year is covered 0.9 times by its yearly operating cash.
Lower than 53% of Healthcare companies in India.
Cash Cushion Ratio
−4%Debt, after subtracting cash, equals 4% of its market value (net debt).
Lower than 64% of Healthcare companies in India.
Tangible Assets Ratio
43%Of every ₹100 the company owns, ₹43 is in tangible assets such as plants, cash, stock and receivables; the rest is goodwill and other intangibles.
Less tangible than 97% of Healthcare companies in India.
Tangible Net Worth Ratio
1%Of every ₹100 of net worth, ₹1 is tangible; the rest is goodwill and other intangibles, often from buying other companies.
Less tangible than 97% of Healthcare companies in India.
Shareholders
Standard fundamentals
P/E, P/B, ROE, debt, growth and more (14)
Mankind Pharma Limited owes ₹0.41 for every ₹1 it owns. Net profit fell 4% in the year to Mar 2026, and grew 14% a year on average over 3 years.
Compared with Healthcare companies in India · latest annual results Mar 2026.
P/E ratio
46.0Investors pay ₹46.0 for every ₹1 of Mankind Pharma Limited's yearly profit, higher than 63% of Healthcare companies in India.
P/B ratio
5.77The share price is 5.77 times Mankind Pharma Limited's book value per share, higher than 64% of Healthcare companies in India.
Market cap
₹93,993 CrThe total market value of all of Mankind Pharma Limited's shares at today's price (share price × number of shares), larger than 94% of Healthcare companies in India. PosiCap size class: Meso Cap.
Net worth (book value)
₹16,300 CrWhat Mankind Pharma Limited would have left on paper if it sold everything it owns and paid everything it owes, from its latest balance sheet (31 Mar 2026).
Book value per share
₹394.64Net worth divided by the number of shares. The share price of ₹2,276 is 5.8 times this, which is the P/B above.
Return on equity (ROE)
12.5%Mankind Pharma Limited earned 12.5% on its shareholders' money over the last year, lower than 52% of Healthcare companies in India.
Owes vs Owns
0.41×Mankind Pharma Limited owes ₹0.41 for every ₹1 it owns (low), higher than 61% of Healthcare companies in India.
Dividend yield
NoneMankind Pharma Limited does not currently pay a dividend.
Revenue growth
+17%Revenue rose 17% in the year to Mar 2026, and grew 18% a year on average over 3 years.
Profit growth
-4%Net profit fell 4% in the year to Mar 2026, and grew 14% a year on average over 3 years.
Profit margin
13.4%Mankind Pharma Limited keeps ₹13 of every ₹100 of revenue as net profit.
Cash quality
1.6×Cash from Mankind Pharma Limited's business was 1.6× its reported profit in the year to Mar 2026 — its profit turned into cash.
Interest cover
4.5×Mankind Pharma Limited's operating profit covered its interest costs 4.5 times in the year to Mar 2026.
Cash vs debt
Net debtMankind Pharma Limited had ₹4,116 Cr more debt than cash (net debt) at Mar 2026.
Questions
What is Mankind Pharma Limited's P/E ratio?
Investors pay ₹46.0 for every ₹1 of Mankind Pharma Limited's yearly profit, higher than 63% of Healthcare companies in India.
How is P/B calculated on PositoAI?
P/B is market cap divided by net worth from the latest balance sheet. For Mankind Pharma Limited: ₹93,993 Cr ÷ ₹16,300 Cr (31 Mar 2026) = 5.8.
What is Mankind Pharma Limited's return on equity?
Mankind Pharma Limited earned 12.5% on its shareholders' money over the last year, lower than 52% of Healthcare companies in India.
How much does Mankind Pharma Limited owe compared with what it owns?
Mankind Pharma Limited owes ₹0.41 for every ₹1 it owns (low), higher than 61% of Healthcare companies in India.
Does Mankind Pharma Limited pay a dividend?
No. Mankind Pharma Limited does not currently pay a dividend.
Is Mankind Pharma Limited's revenue growing?
Revenue rose 17% in the year to Mar 2026, and grew 18% a year on average over 3 years.
Figures from the company's yearly results and PositoAI's own data. Full tables are on the Go Deep tab. What each figure means. PositoAI is for research and education only and is not investment advice.